LIANY · LianBio · Metrics
Market Cap
$5.30M
Shares
108.06M
LIANY metrics
46 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$0.06
Market cap
$5.30M
Price action
20 metricsPrice change (1W)
+56.6%
Price change (30D)
+35.2%
Price change (3M)
-46.4%
Price change (6M)
-63.9%
Price change (YTD)
-37.4%
Price change (1Y)
+10.2%
Trailing year
Price change (5Y)
—
52-week high
$0.18
52-week low
$0.03
Change from 52-week high
-66.4%
Change from 52-week low
+85.9%
Annualized volatility
229.8%
Annualized volatility (3M)
—
Beta
-1.9
RSI (14D)
52.9
Price vs SMA 50
-25.3%
Price vs SMA 200
-29.7%
Avg volume (3M)
34,854
Relative volume
0.0
Average dollar volume
$1,832
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
108.06M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.0
reciprocal yield 3,821.3%
FCF yield
-1,586.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,661.6%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$106.56M
Net income (TTM)
−$87.98M
Trailing 12 months
Diluted EPS (TTM)
$-0.81
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-1.1%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-43.5%
Return on assets
-33.5%
Debt / equity
—
Current ratio
10.1
EBITDA (TTM)
—
Free cash flow (TTM)
−$83.99M
Quick ratio
10.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$252.22M
Latest balance sheet
Cash & equivalents
$103.46M
Total assets
$262.90M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$83.53M
Capital expenditures (TTM)
$464,000
R&D (TTM)
$39.88M
SG&A (TTM)
—
Stock compensation (TTM)
$18.52M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
25 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—